Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced today that it continues to expand the range and application of its respiratory masks with the introduction of four new mask models.
The company introduced a range of three new masks for use in non-invasive ventilation (NIV) at the European Respiratory Society Congress held in Copenhagen this week. Based on the company’s innovative masks for use in the treatment of obstructive sleep apnea (OSA), the range includes nasal, full face and oral masks for use by hospital and homecare patients.
“We are delighted to be employing our very successful mask technology in this new application. Non- invasive ventilation is a rapidly growing therapy in the respiratory care field and these new masks will allow us to serve a large additional group of patients,” commented Michael Daniell, Fisher & Paykel Healthcare’s Chief Executive Officer.
In addition, a new compact nasal mask for use in OSA treatment will be introduced next month at the Medtrade Exhibition in Atlanta, Georgia. The FlexiFit™ 406 Petite Nasal Mask meets the needs of finer featured patients who the company believes are not currently well catered for in the OSA market. The new mask further expands the range of comfortable, easy to fit masks offered by the company and incorporates Fisher & Paykel Healthcare’s FlexiFit™ cushion technology.
“The FlexiFit™ 406 Petite will extend the application of our popular nasal mask range to patients who prefer a very small mask. We believe this addition to our range of masks will contribute to a continuation of strong revenue growth and market share gains in our OSA product group,” said Mr Daniell.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of heated humidification products and systems for use in respiratory care and the treatment of obstructive sleep apnea. It also offers an innovative range of patient warming devices and neonatal care products. The company’s products are sold in over 90 countries worldwide. For more information about the company visit www.fphcare.com.
Contact: Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay CFO on +64 9 574 0119.